Equillium Stock Investor Sentiment

EQ Stock  USD 0.71  0.01  1.39%   
Slightly above 68% of Equillium's investor base is looking to short. The analysis of the overall investor sentiment regarding Equillium suggests that many traders are alarmed. Equillium's investing sentiment overview a quick insight into current market opportunities from investing in Equillium. Many technical investors use Equillium stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Equillium Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Equillium can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at simplywall.st         
Why Investors Shouldnt Be Surprised By Equillium, Inc.s 35 percent Share Price Plunge
Simply Wall St News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 10000 shares by Jason Keyes of Equillium at 0.7 subject to Rule 16b-3
Macroaxis News
over a week ago at businesswire.com         
Equillium to Present at the Stifel Healthcare Conference
businesswire News
over a week ago at seekingalpha.com         
Equillium GAAP EPS of 0.00 misses by 0.02, revenue of 12.16M beats by 0.61M
seekingalpha News
over a week ago at finance.yahoo.com         
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Yahoo News
over a week ago at businesswire.com         
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
businesswire News
over a week ago at zacks.com         
Opus Genetics, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over two weeks ago at news.google.com         
Equillium, Inc. to Report Q3 Results Wall Street Expects Earnings Growth - Yahoo Finance
Google News at Macroaxis
over three weeks ago at gurufocus.com         
Insider Sale Sr. Vice President and COO Christine Zedelmayer Sells 15,000 Shares of Equillium ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Equillium says Ono not acquiring itolizumab, stock craters 36
seekingalpha News
over three weeks ago at prnewswire.com         
EQ Bank named Brand of the Year by strategy magazine
prnewswire News
over three weeks ago at zacks.com         
Travere Therapeutics Reports Q3 Loss, Tops Revenue Estimates
zacks News
over three weeks ago at businesswire.com         
Equillium Maintains Rights to Itolizumab Following Ono Partnership
businesswire News
over three weeks ago at investing.com         
Equillium COO Christine Zedelmayer sells 18,750 in stock
Investing News at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of 2835 shares by Penny Tom of Equillium at 1.25 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Equillium that are available to investors today. That information is available publicly through Equillium media outlets and privately through word of mouth or via Equillium internal channels. However, regardless of the origin, that massive amount of Equillium data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Equillium news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Equillium relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Equillium's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Equillium alpha.

Equillium Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Joel Rothman of 7742 shares of Equillium at 2.35 subject to Rule 16b-3
09/13/2024
2
Disposition of 38806 shares by Penny Tom of Equillium at 0.85 subject to Rule 16b-3
09/16/2024
3
Emotional Intelligence The Art Of Perspective
09/18/2024
4
Lacklustre Performance Is Driving Equillium, Inc.s 28 percent Price Drop
09/26/2024
5
How To Practice Empathy And Boost EQ 17 Leadership Tips
09/30/2024
6
Equillium Stock Price Up 1.7 percent Should You Buy
10/10/2024
7
Disposition of 683 shares by Penny Tom of Equillium at 1.25 subject to Rule 16b-3
10/25/2024
8
Disposition of 2835 shares by Penny Tom of Equillium at 1.25 subject to Rule 16b-3
10/28/2024
9
Insider Sale Sr. Vice President and COO Christine Zedelmayer Sells 15,000 Shares of Equillium ...
10/31/2024
10
Opus Genetics, Inc. Reports Q3 Loss, Tops Revenue Estimates
11/12/2024
11
Equillium GAAP EPS of 0.00 misses by 0.02, revenue of 12.16M beats by 0.61M
11/13/2024
12
Disposition of 10000 shares by Jason Keyes of Equillium at 0.7 subject to Rule 16b-3
11/14/2024

Additional Tools for Equillium Stock Analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.